Showing results (1151-1160 of 8,893) with videos related to

Sort By:
Pageof 890
Schizophrenia Research|March 26, 2013
Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophreniaMichael F Egan, Xin Zhao, Regina Gottwald, et al.
Schizophrenia Research|May 16, 2013
Reduced functional connectivity and asymmetry of the planum temporale in patients with schizophrenia and first-degree relativesViola Oertel-Knöchel, Christian Knöchel, Silke Matura, et al.
Schizophrenia Research|May 21, 2013
Analysis of CpG SNPs in 34 genes: association test with suicide attempt in schizophreniaAli Bani-Fatemi, Vanessa F Gonçalves, Clement Zai, et al.
Schizophrenia Research|March 12, 2013
Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS scoreVenkatesh Pilla Reddy, Magdalena Kozielska, Ahmed Abbas Suleiman, et al.
Schizophrenia Research|March 14, 2013
Psychiatric symptom versus neurocognitive correlates of diminished expressivity in schizophrenia and mood disordersAlex S Cohen, Yunjung Kim, Gina M Najolia
Schizophrenia Research|December 12, 2012
Orbitofrontal cortex abnormality and deficit schizophreniaNobuhisa Kanahara, Yoshimoto Sekine, Tadashi Haraguchi, et al.
Schizophrenia Research|December 14, 2012
Memory functioning and negative symptoms as differential predictors of social problem solving skills in schizophreniaJoseph Ventura, Shelley R Tom, Chris Jetton, et al.
Schizophrenia Research|December 15, 2012
Thioredoxin, a novel oxidative stress marker and cognitive performance in chronic and medicated schizophrenia versus healthy controlsXiang Yang Zhang, Da Chun Chen, Mei Hong Xiu, et al.
Schizophrenia Research|January 5, 2013
Functional connectivity of left Heschl's gyrus in vulnerability to auditory hallucinations in schizophreniaAnn K Shinn, Justin T Baker, Bruce M Cohen, et al.
Schizophrenia Research|February 19, 2013
Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trialAntony Loebel, Josephine Cucchiaro, Kaushik Sarma, et al.
Pageof 890